<DOC>
	<DOCNO>NCT02163694</DOCNO>
	<brief_summary>The study seek evaluate efficacy tolerability veliparib/placebo combination carboplatin paclitaxel HER2-negative metastatic locally advanced , unresectable , BRCA-associated breast cancer .</brief_summary>
	<brief_title>A Phase 3 Randomized , Placebo-controlled Trial Carboplatin Paclitaxel With Without Veliparib ( ABT-888 ) HER2-negative Metastatic Locally Advanced Unresectable BRCA-associated Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Veliparib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Poly ( ADP-ribose ) Polymerase Inhibitors</mesh_term>
	<criteria>1 . Histologically cytologically confirm breast cancer either locally advanced metastatic . Locally advanced breast cancer must amenable surgical resection radiation curative intent . 2 . Suspected deleterious deleterious BRCA1 and/or BRCA2 germline mutation . 3 . Breast cancer must HER2negative . 4 . Measurable nonmeasurable ( radiologically evaluable ) disease per Response Evaluation Criteria In Solid Tumors ( RECIST ) , version 1.1 compute tomography ( CT ) scan ( within 28 day randomization ) least one lesion outside previously irradiate area . 5 . ECOG Performance status 0 2 . 6 . Adequate hematologic , renal , hepatic function ( within 28 day randomization ) . 1 . More two prior line cytotoxic chemotherapy ( e.g. , gemcitabine , doxorubicin , capecitabine ) metastatic disease . Regimens received adjuvant/neoadjuvant set locally advance breast cancer within past 6 month also consider toward maximum 2 prior line therapy . Adjuvant/neoadjuvant chemotherapy one cancer event count one prior line therapy , receive within past 6 month . Previous treatment hormonal therapy ( tamoxifen , aromatase inhibitor ) signal transduction agent ( e.g. , erlotinib , gefitinib , everolimus , bevacizumab ) allow count towards prior line therapy . 2 . Progressed recur within 12 month complete platinum therapy receive &gt; 1 prior line platinum therapy breast cancer setting ( adjuvant neoadjuvant ) . 3 . Prior therapy PARP inhibitor . 4 . Prior taxane therapy administer treatment metastatic breast cancer exception . Prior taxane therapy metastatic breast cancer allow patient receive â‰¤ 1 full cycle ( i.e. , therapy discontinue within 4 week subject receive weekly paclitaxel Abraxane ; therapy discontinue within 3 week subject receive paclitaxel docetaxel every 3 week ) absence progression taxane therapy metastatic disease &gt; 12 month prior C1D2 . Use taxanes adjuvant therapy treat locally advanced disease permit , give 6 month prior C1D2 5 . Known history allergic reaction cremophorpaclitaxel , carboplatin , AzoColourant Tartrazine ( also know FD &amp; C Yellow 5 E102 ) , AzoColourant Orange YellowS ( also know FD &amp; C Yellow 6 E110 ) know contraindication study supply drug . 6 . Active CNS metastases leptomeningeal disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>BRCA2</keyword>
	<keyword>BRCA Mutation</keyword>
	<keyword>BRCA1</keyword>
	<keyword>ABT-888</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Metastatic Breast Cancer</keyword>
	<keyword>PARP</keyword>
	<keyword>Genetic breast cancer</keyword>
	<keyword>Veliparib</keyword>
	<keyword>Locally recurrent</keyword>
	<keyword>PARP Inhibitor</keyword>
	<keyword>HER2-negative</keyword>
</DOC>